Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema
Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to Bevacizumab.
- Trial name
- NCT01253694
- Testing
- injection of 0.5 mg of Intravitreal Ranibizumab
- Where
- United States
- Sponsor
- New England Retina Associates
Macular Edema, Central Serous Chorioretinopathy
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Laser photocoagulation of the retina targeting the outer layers is an established therapy for proliferative retinopathy and macular edema from diabetic microangiopathy or retinal vein occlusion, centrals serous retinopathy, and…
- Conditions
- Macular Edema, Central Serous Chorioretinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
- Trial name
- NCT02088151
- Testing
- Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Wet Macular Degeneration
To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
To describe the use of intravitreal aflibercept in routine clinical practice and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Canada for a study population of…
- Trial name
- PEGASUS (NCT02540369)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 2,150 people
- Sponsor
- Bayer
Diabetic Macular Edema, Vitreomacular Interface
Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors
- Conditions
- Diabetic Macular Edema, Vitreomacular Interface, Anti-VEGF Treatment
- Trial name
- NCT02933905
- Testing
- Intravitreal Ranibizumab injection
- Volunteers
- 38 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Diffuse Diabetic Macular Edema
POSTERIOR SUB-TENON'S Avastin
Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema
- Trial name
- NCT00567372
- Testing
- bevacizumab (Sub-tenon´s injection)
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Macular Edema
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
- Trial name
- NCT04795037
- Testing
- CU06-1004, Single dose, CU06-1004, Multiple doses
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Curacle Co., Ltd.
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BRUNELLO (NCT06571045)
- Testing
- Ranibizumab, Remigromig
- Where
- 183 sites in United States, Argentina and 18 more
- Volunteers
- 984 people
- Sponsor
- EyeBiotech Ltd.
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
Patients with proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring surgical intervention will receive a pre-operative injection of Macugen.
- Trial name
- PEGAP001 (NCT00446381)
- Testing
- Macugen (pegaptanib)
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this…
- Trial name
- NCT07553429
- Testing
- Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
The Results of Pars Plana Vitrectomy in Diabetic Macular Edema
This study will be a retrospective analysis of vitrectomy results in patients suffering from diabetic macular edema.
- Trial name
- NCT03384901
- Testing
- vitrectomy
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Hillel Yaffe Medical Center
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Diabetic Macular Edema Treated With Ozurdex (DMEO)
To measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent diabetic macular edema
- Trial name
- DMEO (NCT01951066)
- Testing
- Dexamethasone Implant, Anti-VEGF injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Cystoid Macular Edema, Postoperative, Diabetes Mellitus
Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients
The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract…
- Trial name
- NCT02646072
- Testing
- Ketorolac tromethamine ophthalmic solution 0.45%
- Where
- Malaysia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Diabetic Macular Edema (DME)
Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema
Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss.
- Trial name
- Macular Edema (NCT07897630)
- Testing
- Bevacizumab
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Khyber Teaching Hospital
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg)…
- Trial name
- Pagoda (NCT04108156)
- Testing
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange
- Where
- 89 sites in United States
- Volunteers
- 672 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema, Visual Impairment
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these…
- Conditions
- Diabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic)
- Trial name
- BiomarkerOCT (NCT06984822)
- Testing
- Anti-VEGF treatment, Dexamethasone implant, Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Where
- 2 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Vastra Gotaland Region
Diabetic Macular Edema
Dextromethorphan for Diabetic Macular Edema
Background: Many people with diabetes have macular edema (swelling) at the back of the eye. Macular edema can cause loss of vision. Studies suggest that inflammation may be involved in the swelling.
- Trial name
- MiDME2 (NCT01441102)
- Testing
- Dextromethorphan hydrobromide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals